Haemophagocytic lymphohistiocytosis (HLH) with concurrent Hodgkin's Disease.
No Thumbnail Available
All Authors
Ambrose Fistus, V.
Sharief, M.
Sarma, A.
LTHT Author
Sarma, Anita
LTHT Department
Oncology
Haematology
Haematology
Non Medic
Publication Date
2025
Item Type
Journal Article
Case Reports
Case Reports
Language
Subject
Subject Headings
Abstract
Haemophagocytic lymphohistiocytosis (HLH) is a condition of uncontrolled immune activation caused by genetic defects or triggered by infections, malignancies, autoimmune diseases, drugs, pregnancy or post-transplant immunosuppression. This case describes a young man presenting with clinical jaundice and abnormal blood tests, including raised inflammatory markers, abnormal liver function, low haemoglobin (65 g/L) and a low white blood cell count (3.08x109/L). He met five out of eight HLH criteria and tested positive for Epstein-Barr virus (EBV) PCR (58 011 IU/mL). His bone marrow biopsy showed EBV-driven Hodgkin's lymphoma. He was initially treated with the HLH-94 protocol and later switched to ABVD chemotherapy (adriamycin, bleomycin, vinblastine and dacarbazine). He steadily recovered despite a prolonged hospital stay. He was discharged to complete his remaining cycles of chemotherapy as an outpatient with a plan of having a positron emission tomography (PET) scan after two cycles of chemotherapy.
Journal
BMJ Case Reports